A forthcoming congressional bill aimed at establishing new federal hemp regulation is reportedly facing opposition from a diverse coalition of industry stakeholders. Representative Andy Barr (R-KY) indicated in a meeting with hemp industry representatives that sectors of the alcohol industry, marijuana businesses, and cannabis legalization opponents are resisting the proposed legislation.
This development highlights the complex interplay of economic interests and policy objectives within the broader cannabis and beverage sectors, as detailed by Marijuana Moment. The opposition suggests a strategic alignment among groups that typically have differing policy stances, united by concerns regarding market competition or regulatory frameworks.
Legislative and Regulatory Developments in Hemp
Beyond the proposed federal bill, several other legislative and regulatory actions are shaping the landscape for industrial hemp and its derivatives. The U.S. Department of Agriculture (USDA) is currently seeking approval from the White House Office of Management and Budget (OMB) for information collection related to state and tribal hemp plans. This process is a standard step in refining and implementing federal oversight for hemp cultivation and processing.
Concurrently, a House bill designed to delay the recriminalization of hemp products has gained an additional cosponsor, bringing its total to 34. This legislative effort underscores ongoing industry concerns regarding the legal status of certain hemp products and the potential for regulatory shifts to impact market stability. In Texas, hemp business owners have reported significant operational challenges, including reduced hours and staff cuts, due to conflicting court rulings that have alternately paused and reinstated a ban on smokable hemp products.
Policy Shifts in Cannabis and Psychedelics
The broader policy environment for cannabis and psychedelics also continues to evolve. The Drug Enforcement Administration (DEA) has clarified that a question on its medical cannabis business registration form regarding previous unregistered involvement with controlled substances is “not intended to serve as a categorical barrier” to approval. This clarification may offer some reassurance to prospective medical cannabis operators with prior history.
In a notable development, Senator John Fetterman (D-PA) publicly acknowledged President Donald Trump’s actions regarding marijuana rescheduling and the acceleration of access to psychedelics for therapeutic research. These comments reflect a bipartisan recognition of potential shifts in federal drug policy. Furthermore, Virginia Governor Abigail Spanberger (D) signed legislation providing resentencing relief for individuals with marijuana convictions, following earlier legislative debates over the scope of the reform.
New Jersey lawmakers are also considering a bill that would permit sales of large-container hemp beverages and allow medical cannabis dispensaries to incorporate adult-use marijuana sales without requiring additional local approval. This move could streamline operations for existing medical cannabis businesses and expand market access for hemp-derived products.
Medical Cannabis Access and Therapeutic Research
Access to medical cannabis continues to expand in various jurisdictions. Alabama is preparing for the imminent opening of its first medical cannabis dispensary, nearly five years after the state’s lawmakers enacted legalization. This opening represents a significant step in providing regulated access to patients in the state.
Scientific inquiry into the potential applications of cannabinoids also continues to advance. A recent scientific review highlighted the “potential of CBD as an anticancer agent across different cancer types” in dogs. The review found that studies “consistently show” that cannabidiol “exerts antiproliferative and proapoptotic effects” and is “safe and well-tolerated in dogs.” Separately, another review concluded that “cannabinoids hold significant potential to address diseases driven by inflammation and oxidative stress and to expand therapeutic landscape,” suggesting broader applications for cannabinoid-based therapies.
Industry Operations and Enforcement
Regulatory enforcement and market dynamics remain key considerations for industry operators. Oklahoma’s attorney general has noted marijuana enforcement efforts in a press release discussing public safety initiatives. Separately, Oklahoma regulators expanded a recall of medical cannabis products, indicating ongoing oversight of product quality and safety. Michigan regulators also published a monthly report detailing disciplinary actions taken against marijuana businesses, underscoring the active role of state authorities in maintaining compliance.
On the business front, Ascend Wellness Holdings is reportedly closing a cultivation facility in Lansing, Michigan. Additionally, Good Day Farm is facing a lawsuit from a consumer alleging the company and its affiliated LLCs utilized a network of marijuana dispensary licenses to limit competition and inflate prices. These instances reflect the operational and legal challenges that can arise within the evolving cannabis market.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
